Activation of dopamine receptor D2 to inhibit non-small cell lung cancer growth in vivo.

e23197Background: Lung cancer ranks the first cancer related mortality worldwide. Dysregulation of dopamine-related pathways have been implicated in tumor development/angiogenesis. Methods: In this study, dopamine receptor D2 (DRD2) agonist, quinpirole, was utilized to treat nude mice which burden A549 xenograft. The tumor size and mice body weight were measured in 3 days. In the end point, tumor/heart/liver/spleen weight was measured. IHC analyzed Ki-67 and p65 in control and quinpirole group to identify the difference of tumor growth and NF-κB signal pathway. Results: DRD2 agonist, quinpirole inhibits NSCLC tumor growth (P < 0.0001). In addition, the usage of quinpirole has no side effect to mice heart/liver/spleen. This chemical not only decreases the tumor proliferation, but also inhibits NF-κB signal pathway in tumor cells. Conclusions: Our data indicates that the activation of DRD2 decreases NSCLC tumors growth through abrogation of NF-κB signal pathway ,and the axis might be a novel therapeutic str...